VALNEVA Reports Annual Results 2014: the company announces a significant improvement to its EBITDA and a strong reduction of its net loss
March 20, 2015 02:30 ET
|
VALNEVA
Valneva Reports Annual Results 2014 The company announces a significant improvement to its EBITDA and a strong reduction of its net loss compared to prior-year pro forma result Significant...
VALNEVA announces signing of an exclusive license agreement on EB66(r) Cell Line for Human and Veterinary Vaccines in China
March 17, 2015 02:58 ET
|
VALNEVA
LYON, France, March 17, 2015 (GLOBE NEWSWIRE) -- Valneva announces signing of an exclusive license agreement on EB66® Cell Line for Human and Veterinary Vaccines in People's Republic of...
VALNEVA annonce la signature d'un accord de licence exclusif sur la lignée cellulaire EB66® pour la production de vaccins humains et vétérinaires en Chine
March 17, 2015 02:30 ET
|
VALNEVA
Valneva annonce la signature d'un accord de licence exclusif sur la lignée cellulaire EB66® pour la production de vaccins humains et vétérinaires en République populaire de Chine Le partenaire...
VALNEVA announces signing of an exclusive license agreement on EB66® Cell Line for Human and Veterinary Vaccines in China
March 17, 2015 02:30 ET
|
VALNEVA
Valneva announces signing of an exclusive license agreement on EB66® Cell Line for Human and Veterinary Vaccines in People's Republic of China The partner Jianshun Biosciences Ltd is granted...
VALNEVA announces signing of an exclusive license agreement on EB66® Cell Line for Human and Veterinary Vaccines in China
March 17, 2015 02:30 ET
|
VALNEVA
Valneva announces signing of an exclusive license agreement on EB66® Cell Line for Human and Veterinary Vaccines in People's Republic of China The partner Jianshun Biosciences Ltd is granted...
VALNEVA annonce la signature de deux nouveaux accords de licence pour sa plateforme cellulaire EB66® :
March 11, 2015 02:30 ET
|
VALNEVA
Valneva annonce la signature de deux nouveaux accords de licence pour sa plateforme cellulaire EB66® : - Licence de recherche avec un acteur majeur en santé animale, - Licence...
VALNEVA Announces Two New Deals on its EB66® Vaccine Cell Line Platform
March 11, 2015 02:30 ET
|
VALNEVA
Valneva Announces Two New Deals on its EB66® Vaccine Cell Line Platform: - New EB66® Research License Agreement with global animal health company, - New EB66® Commercial license...
VALNEVA Announces Two New Deals on its EB66® Vaccine Cell Line Platform
March 11, 2015 02:30 ET
|
VALNEVA
Valneva Announces Two New Deals on its EB66® Vaccine Cell Line Platform: - New EB66® Research License Agreement with global animal health company, - New EB66® Commercial license...
VALNEVA : Déclaration d'actions et de droits de vote - FEVRIER 2015
March 04, 2015 02:50 ET
|
VALNEVA
VALNEVA Déclaration d'actions et de droits de vote - FEVRIER 2015 Dénomination sociale : VALNEVA Adresse du siège social : 70, rue Saint Jean de Dieu, 69007 LYON Marché réglementé Euronext Paris...
VALNEVA Reports Significantly Improved Preliminary Full Year 2014 Results
February 26, 2015 01:30 ET
|
VALNEVA
Valneva Reports Significantly Improved Preliminary Full Year 2014 Results The Company today announced preliminary (unaudited) Q4 2014 and FY 2014 Financial Results + Total FY 2014 revenues...